You are here: Help and Support Resources » COVID-19 Coronavirus Project » Preliminary Report - ID Mapping

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

- Both sides previous revision Previous revision
Next revision
- covid:unpublished [2020/06/02 13:32] biogridadmin
+ Previous revision
+ covid:unpublished [2021/04/24 15:17] (current) biogridadmin
@@ Line -5,31 +5,181 @@ removed created
 
 **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/​health-related behavior, or be reported in news media as established information.
   
 ^  Custom ID  ^  DOI  ^  ​Author ​AUTHOR ​ ​^ ​Dataset ​DATASET ​ ^ 
 |  **888800000001** ​ |  **[[https://​doi.org/​10.1101/​2020.03.22.002386|10.1101/​2020.03.22.002386]]** ​ |  Gordon DE (2020) ​ | **[[https://​thebiogrid.org/​220839/​publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** ​ |
 |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ |
 |  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  ​Xie L Sun C (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]**  | 
 |  **888800000004** ​ |  **[[https://​doi.org/​10.1101/​2020.03.16.994236|10.1101/​2020.03.16.994236]]** ​ |  Procko E (2020) ​ | **[[https://​thebiogrid.org/​221182/​publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]**  |
 |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ |
 |  **888800000006** ​ |  **[[https://​doi.org/​10.1101/​2020.02.17.951848|10.1101/​2020.02.17.951848]]** ​ |  Zhou Q (2020) ​ | **[[https://​thebiogrid.org/​221185/​publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** ​ |
 |  **888800000007** ​ |  **[[https://​doi.org/​10.1101/​2020.02.26.964882|10.1101/​2020.02.26.964882]]** ​ |  Jin Z (2020) ​ | **[[https://​thebiogrid.org/​221186/​publication|Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]]]** ​ |
 |  **888800000008** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.013490|10.1101/​2020.03.29.013490]]** ​ |  Wang C (2020) ​ | **[[https://​thebiogrid.org/​221195/​publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** ​ |
 |  **888800000009** ​ |  **[[https://​doi.org/​10.1101/​2020.03.25.996348|10.1101/​2020.03.25.996348]]** ​ |  Dai W (2020) ​ | **[[https://​thebiogrid.org/​221196/​publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** ​ |
 |  **888800000010** ​ |  **[[https://​doi.org/​10.1101/​2020.03.15.992883|10.1101/​2020.03.15.992883]]** ​ |  Joyce MG (2020) ​ | **[[https://​thebiogrid.org/​221197/​publication|A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein]]** ​ |
 |  **888800000011** ​ |  **[[https://​doi.org/​10.1101/​2020.03.16.993386|10.1101/​2020.03.16.993386]]** ​ |  Gao Y (2020) ​ | **[[https://​thebiogrid.org/​221198/​publication|Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target]]** ​ |
 |  **888800000012** ​ |  **[[https://​doi.org/​10.1101/​2020.03.31.019216|10.1101/​2020.03.31.019216]]** ​ |  Liang Q (2020) ​ | **[[https://​thebiogrid.org/​221199/​publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** ​ |
 |  **888800000013** ​ |  **[[https://​doi.org/​10.1101/​2020.04.15.042085|10.1101/​2020.04.15.042085]]** ​ |  Bestle D (2020) ​ | **[[https://​thebiogrid.org/​221402/​publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** ​ |
 |  **888800000014888800000018**  |  **[[https://​doi.org/​10.1101/​2020.04.0919.033233049643|10.1101/​2020.04.0919.033233049643]]**  |  ​Jin Z Zeng X (2020) ​ | **[[https://​thebiogrid.org/​221403221566/​publication|Structural basis for Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy]]** ​ | 
 |  **888800000020** ​ |  **[[https://​doi.org/​10.1101/​2020.04.22.046565|10.1101/​2020.04.22.046565]]** ​ |  Liu Y (2020) ​ | **[[https://​thebiogrid.org/​221568/​publication|Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2]]** ​ | 
 |  **888800000021** ​ |  **[[https://​doi.org/​10.1101/​2020.04.21.053017|10.1101/​2020.04.21.053017]]** ​ |  Walker A (2020) ​ | **[[https://​thebiogrid.org/​221569/​publication|Enisamium is a small molecule inhibitor of the inhibition ​influenza A virus and SARS-CoV-2 RNA polymerases]]** ​ | 
 |  **888800000022** ​ |  **[[https://​doi.org/​10.1101/​2020.04.17.047498|10.1101/​2020.04.17.047498]]** ​ |  Rosas Lemus M (2020) ​ | **[[https://​thebiogrid.org/​221570/​publication|The crystal structure ​of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine]]** ​ | 
 |  **888800000025** ​ |  **[[https://​doi.org/​10.1101/​2020.04.29.068890|10.1101/​2020.04.29.068890]]** ​ |  Rut W (2020) ​ | **[[https://​thebiogrid.org/​221777/​publication|Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 ​drug design]]** ​ | 
 |  **888800000029** ​ |  **[[https://​doi.org/​10.1101/​2020.05.02.20086876|10.1101/​2020.05.02.20086876]]** ​ |  Zhang D (2020) ​ | **[[https://​thebiogrid.org/​221831/​publication|Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)]]** ​ | 
 |  **888800000031** ​ |  **[[https://​doi.org/​10.1101/​2020.05.06.079830|10.1101/​2020.05.06.079830]]** ​ |  Zha L (2020) ​ | **[[https://​thebiogrid.org/​221833/​publication|Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles]]** ​ | 
 |  **888800000032** ​ |  **[[https://​doi.org/​10.1101/​2020.05.02.043554|10.1101/​2020.05.02.043554]]** ​ |  Gunther S (2020) ​ | **[[https://​thebiogrid.org/​221835/​publication|Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 ​main protease]]**  | 
 |  **888800000034** ​ |  **[[https://​doi.org/​10.1101/​2020.05.03.074914|10.1101/​2020.05.03.074914]]** ​ |  Liu X (2020) ​ | **[[https://​thebiogrid.org/​221959/​publication|Neutralizing Antibodies Isolated ​by carmofur, an antineoplastic druga site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]**  | 
 |  **888800000015888800000035**  |  **[[https://​doi.org/​10.1101/​2020.0405.0821.032763109157|10.1101/​2020.0405.0821.032763109157]]**  |  ​Yin W Lui I (2020) ​ | **[[https://​thebiogrid.org/​221404222215/​publication|Structural Basis for Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity]]** ​ | 
 |  **888800000036** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.107870|10.1101/​2020.05.21.107870]]** ​ |  Partridge LJ (2020) ​ | **[[https://​thebiogrid.org/​222216/​publication|Unfractionated heparin potently inhibits ​the Inhibition ​binding ​of SARS-CoV-2 spike protein to a human cell line]]** ​ | 
 |  **888800000037** ​ |  **[[https://​doi.org/​10.1101/​2020.05.13.092478|10.1101/​2020.05.13.092478]]** ​ |  Chiodo F (2020) ​ | **[[https://​thebiogrid.org/​222217/​publication|Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota]]** ​ | 
 |  **888800000038** ​ |  **[[https://​doi.org/​10.1101/​2020.05.12.091298|10.1101/​2020.05.12.091298]]** ​ |  Seydoux E (2020) ​ | **[[https://​thebiogrid.org/​222218/​publication|Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual]]** ​ | 
 |  **888800000040** ​ |  **[[https://​doi.org/​10.1101/​2020.05.12.092171|10.1101/​2020.05.12.092171]]** ​ |  Zhou X (2020) ​ | **[[https://​thebiogrid.org/​222220/​publication|Structure of SARS-CoV-2 main protease in the RNAapo state reveals the inactive conformation]]** ​ | 
 |  **888800000041** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.156455|10.1101/​2020.06.17.156455]]** ​ |  Stukalov A (2020) ​ | **[[https://​thebiogrid.org/​222410/​publication|Multi-Dependent RNA Polymerase ​level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV]]** ​ | 
 |  **888800000042** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.135921|10.1101/​2020.06.05.135921]]** ​ |  Bertoglio F (2020) ​ | **[[https://​thebiogrid.org/​222602/​publication|SARS-CoV-2 neutralizing human recombinant antibodies selected ​from pre-pandemic healthy donors binding at RBD-ACE2 interface]]** ​ | 
 |  **888800000043** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.135699|10.1101/​2020.06.05.135699]]** ​ |  Moustaqil M (2020) ​ | **[[https://​thebiogrid.org/​222603/​publication|SARS-CoV-2 ​by Remdesivirproteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.]]**  | 
 |  **888800000016888800000046**  |  **[[https://​doi.org/​10.1101/​2020.0406.1417.042010158121|10.1101/​2020.0406.1417.042010158121]]**  |  ​Chi Cubuk J (2020) ​ | **[[https://​thebiogrid.org/​222654/​publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** ​ | 
 |  **888800000050** ​ |  **[[https://​doi.org/​10.1101/​2020.06.07.138677|10.1101/​2020.06.07.138677]]** ​ |  Luan X (2020) ​ | **[[https://​thebiogrid.org/​221405222705/​publication|Humanized Single Domain Antibodies Neutralize ​Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376]]** ​ | 
 |  **888800000052** ​ |  **[[https://​doi.org/​10.1101/​2020.06.06.137513|10.1101/​2020.06.06.137513]]** ​ |  Lou Y (2020) ​ | **[[https://​thebiogrid.org/​222707/​publication|Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries]]** ​ | 
 |  **888800000054** ​ |  **[[https://​doi.org/​10.1101/​2020.06.16.155812|10.1101/​2020.06.16.155812]]** ​ |  Li J (2020) ​ | **[[https://​thebiogrid.org/​222709/​publication|Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin]]** ​ | 
 |  **888800000056** ​ |  **[[https://​doi.org/​10.1101/​2020.06.16.154708|10.1101/​2020.06.16.154708]]** ​ |  Hanson QM (2020) ​ | **[[https://​thebiogrid.org/​223039/​publication|Targeting ​ACE2-RBD interaction as a platform for COVID19 therapeutics:​ Development and drug repurposing screen of an AlphaLISA proximity assay]]** ​ | 
 |  **888800000063** ​ |  **[[https://​doi.org/​10.1101/​2020.07.31.230730|10.1101/​2020.07.31.230730]]** ​ |  Cao W (2020) ​ | **[[https://​thebiogrid.org/​223096/​publication|Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction]]** ​ | 
 |  **888800000064** ​ |  **[[https://​doi.org/​10.1101/​2020.07.24.219857|10.1101/​2020.07.24.219857]]** ​ |  Esparza TJ (2020) ​ | **[[https://​thebiogrid.org/​223097/​publication|High Affinity Nanobodies Block SARS-CoV-2 ​Spike Receptor Binding Domain ​Interaction with Human Angiotensin Converting Enzyme]]**  | 
 |  **888800000017888800000065**  |  **[[https://​doi.org/​10.1101/​2020.0407.0625.20055475221036|10.1101/​2020.0407.0625.20055475221036]]**  |  ​Ye L Shilts J (2020) ​ | **[[https://​thebiogrid.org/​221565223098/​publication|No evidence for basigin/humanCD147 as a direct SARS-monoclonalCoV-antibodies2 spike binding receptor]]** ​ | 
 |  **888800000066** ​ |  **[[https://​doi.org/​10.1101/​2020.07.13.201517|10.1101/​2020.07.13.201517]]** ​ |  Davies JP (2020) ​ | **[[https://​thebiogrid.org/​223099/​publication|Comparative multiplexed interactomics of SARS-blockCoV-the2 and homologous coronavirus non-bindingstructural proteins identifies unique and shared host-cell dependencies]]** ​ | 
 |  **888800000067** ​ |  **[[https://​doi.org/​10.1101/​2020.07.31.229781|10.1101/​2020.07.31.229781]]** ​ |  Alitongbieke G (2020) ​ | **[[https://​thebiogrid.org/​223100/​publication|Study on beta-Chitosan against the binding ​of SARS-sarsCoV-cov2S-2RBD/​ACE2]]** ​ | 
 |  **888800000069** ​ |  **[[https://​doi.org/​10.1101/​2020.07.27.224089|10.1101/​2020.07.27.224089]]** ​ |  Beasley MD (2020) ​ | **[[https://​thebiogrid.org/​223102/​publication|Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries]]** ​ | 
 |  **888800000070** ​ |  **[[https://​doi.org/​10.1101/​2020.07.29.227462|10.1101/​2020.07.29.227462]]** ​ |  Gao C (2020) ​ | **[[https://​thebiogrid.org/​223103/​publication|SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors]]** ​ | 
 |  **888800000071** ​ |  **[[https://​doi.org/​10.1101/​2020.07.26.222026|10.1101/​2020.07.26.222026]]** ​ |  Zheng Y (2020) ​ | **[[https://​thebiogrid.org/​223104/​publication|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling]]** ​ | 
 |  **888800000072** ​ |  **[[https://​doi.org/​10.1101/​2020.07.30.229187|10.1101/​2020.07.30.229187]]** ​ |  Shi W (2020) ​ | **[[https://​thebiogrid.org/​223105/​publication|A dynamic regulatory interface on SARS-CoV-2 RNA polymerase]]** ​ | 
 |  **888800000075** ​ |  **[[https://​doi.org/​10.1101/​2020.07.15.204404|10.1101/​2020.07.15.204404]]** ​ |  Schmidt N (2020) ​ | **[[https://​thebiogrid.org/​223108/​publication|A direct RNA-protein ​interaction atlas of the SARS-toCoV-angiotensin2 RNA in infected human cells]]** ​ | 
 |  **888800000076** ​ |  **[[https://​doi.org/​10.1101/​2020.08.03.234914|10.1101/​2020.08.03.234914]]** ​ |  Cao L (2020) ​ | **[[https://​thebiogrid.org/​223109/​publication|De novo design of picomolar SARS-convertingCoV-enzyme2 miniprotein inhibitors. [DEPRECATED]]]** ​ | 
 |  **888800000078** ​ |  **[[https://​doi.org/​10.1101/​2020.07.17.208959|10.1101/​2020.07.17.208959]]** ​ |  Fu Z (2020) ​ | **[[https://​thebiogrid.org/​223111/​publication|Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules]]** ​ | 
 |  **888800000079** ​ |  **[[https://​doi.org/​10.1101/​2020.07.31.231282|10.1101/​2020.07.31.231282]]** ​ |  Tee KL (2020) ​ | **[[https://​thebiogrid.org/​223112/​publication|Purification of recombinant SARS-CoV-2 spike, its receptor ​binding domain, and CR3022 mAb for serological assay]]** ​ | 
 |  **888800000080** ​ |  **[[https://​doi.org/​10.1101/​2020.07.25.220806|10.1101/​2020.07.25.220806]]** ​ |  Temerozo JR (2020) ​ | **[[https://​thebiogrid.org/​223113/​publication|The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.html]]**  | 
 |  **888800000018888800000081**  |  **[[https://​doi.org/​10.1101/​2020.0408.1903.049643234559|10.1101/​2020.0408.1903.049643234559]]**  |  ​Zeng X Addetia A (2020) ​ | **[[https://​thebiogrid.org/​221566223399/​publication|SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98]]** ​ | 
 |  **888800000082** ​ |  **[[https:/blocking/​doi.org/​10.1101/​2020.08.28.272955|10.1101/​2020.08.28.272955]]** ​ |  Laurent E (2020) ​ | **[[https://​thebiogrid.org/​223400/​publication|Global BioID-antibodiesbased SARS-againstCoV-sars2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-covassociated mechanisms]]** ​ | 
 |  **888800000083** ​ |  **[[https://​doi.org/​10.1101/​2020.08.20.259770|10.1101/​2020.08.20.259770]]** ​ |  Lapointe CP (2020) ​ | **[[https://​thebiogrid.org/​223461/​publication|Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation]]** ​ | 
 |  **888800000084** ​ |  **[[https://​doi.org/​10.1101/​2020.08.16.252973|10.1101/​2020.08.16.252973]]** ​ |  Han L (2020) ​ | **[[https://​thebiogrid.org/​223462/​publication|SARS-rbdCoV-isolated2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-fromI/MDA-a5-phageMAVS, TLR3-displayTRIF, and cGAS-antibodySTING Signaling Pathways]]** ​ | 
 |  **888800000085** ​ |  **[[https://​doi.org/​10.1101/​2020.08.06.238915|10.1101/​2020.08.06.238915]]** ​ |  Watson A (2020) ​ | **[[https://​thebiogrid.org/​223463/​publication|Peptide Antidotes to SARS-libraryCoV-using2 (COVID-a19)]]** ​ | 
 |  **888800000086** ​ |  **[[https://​doi.org/​10.1101/​2020.08.12.247767|10.1101/​2020.08.12.247767]]** ​ |  Yang Z (2020) ​ | **[[https://​thebiogrid.org/​223464/​publication|Suppression of MDA5-competitivemediated antiviral immune responses by NSP8 of SARS-biopanningCoV-strategy2]]**  | 
 |  **888800000087** ​ |  **[[https://​doi.htmlorg/​10.1101/​2020.08.12.246389|10.1101/​2020.08.12.246389]]** ​ |  Risner K (2020) ​ | **[[https://​thebiogrid.org/​223465/​publication|Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture]]**  | 
 |  **888800000019888800000088**  |  **[[https://​doi.org/​10.1101/​2020.0408.2308.057265238469|10.1101/​2020.0408.2308.057265238469]]**  |  ​Peng Q Schoof M (2020) ​ | **[[https://​thebiogrid.org/​221567223466/​publication|An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation]]** ​ | 
 |  **888800000089** ​ |  **[[https:/structural/​doi.org/​10.1101/​2020.08.14.250258|10.1101/​2020.08.14.250258]]** ​ |  Chen Y (2020) ​ | **[[https://​thebiogrid.org/​223467/​publication|Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro]]** ​ | 
 |  **888800000090** ​ |  **[[https://​doi.org/​10.1101/​2020.08.09.242917|10.1101/​2020.08.09.242917]]** ​ |  Thepaut M (2020) ​ | **[[https://​thebiogrid.org/​223468/​publication|DC/​L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection ​and can be inhibited by a glycomimetic antagonist]]** ​ | 
 |  **888800000093** ​ |  **[[https://​doi.org/​10.1101/​2020.08.18.256776|10.1101/​2020.08.18.256776]]** ​ |  Andres AD (2020) ​ | **[[https://​thebiogrid.org/​223471/​publication|SARS-biochemicalCoV-characterization2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells]]** ​ | 
 |  **888800000094** ​ |  **[[https://​doi.org/​10.1101/​2020.08.13.249177|10.1101/​2020.08.13.249177]]** ​ |  Carrique L (2020) ​ | **[[https://​thebiogrid.org/​223473/​publication|The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability ​of the prefusion trimer]]** ​ | 
 |  **888800000095** ​ |  **[[https://​doi.org/​10.1101/​2020.08.13.248211|10.1101/​2020.08.13.248211]]** ​ |  Baddock HT (2020) ​ | **[[https://​thebiogrid.org/​223474/​publication|Characterisation of the SARS-nsp12CoV-nsp72 ExoN (nsp14ExoN-nsp8nsp10) complex: implications for its role in viral genome stability and inhibitor identification]]** ​ | 
 |  **888800000096** ​ |  **[[https://​doi.org/​10.1101/​2020.08.10.244525|10.1101/​2020.08.10.244525]]** ​ |  Malla TN (2020) ​ | **[[https://​thebiogrid.org/​223475/​publication|Ebselen Reacts with SARS Coronavirus-core2 Main Protease Crystals]]** ​ | 
 |  **888800000097** ​ |  **[[https://​doi.org/​10.1101/​2020.08.11.244863|10.1101/​2020.08.11.244863]]** ​ |  Pillon MC (2020) ​ | **[[https://​thebiogrid.org/​223476/​publication|Cryo-polymeraseEM Structures of the SARS-complexCoV-2 Endoribonuclease Nsp15]]** ​ | 
 |  **888800000098** ​ |  **[[https://​doi.org/​10.1101/​2020.08.12.247338|10.1101/​2020.08.12.247338]]** ​ |  Wang C (2020) ​ | **[[https://​thebiogrid.org/​223477/​publication|Membrane Nanoparticles Derived ​from ACE2-covidrich Cells Block SARS-19CoV-virus2 Infection]]** ​ | 
 |  **888800000099** ​ |  **[[https://​doi.htmlorg/​10.1101/​2020.08.14.251421|10.1101/​2020.08.14.251421]]** ​ |  Wilamowski M (2020) ​ | **[[https://​thebiogrid.org/​223478/​publication|Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography]]**  | 
 |  **888800000020888800000100**  |  **[[https://​doi.org/​10.1101/​2020.0408.2213.046565248872|10.1101/​2020.0408.2213.046565248872]]**  |  ​Liu Wei C (2020) ​ | **[[https://​thebiogrid.org/​223479/​publication|SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry]]** ​ | 
 |  **888800000101** ​ |  **[[https://​doi.org/​10.1101/​2020.08.14.251207|10.1101/​2020.08.14.251207]]** ​ |  Heaton BE (2020) ​ | **[[https://​thebiogrid.org/​223480/​publication|SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2]]** ​ | 
 |  **888800000103** ​ |  **[[https://​doi.org/​10.1101/​2020.08.09.242867|10.1101/​2020.08.09.242867]]** ​ |  Gai J (2020) ​ | **[[https://​thebiogrid.org/​223482/​publication|A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential]]** ​ | 
 |  **888800000104** ​ |  **[[https://​doi.org/​10.1101/​2020.09.03.282103|10.1101/​2020.09.03.282103]]** ​ |  Samavarchi-Tehrani P (2020) ​ | **[[https://​thebiogrid.org/​223517/​publication|A SARS-CoV-2 - host proximity interactome]]** ​ | 
 |  **888800000105** ​ |  **[[https://​doi.org/​10.1101/​2020.09.09.287508|10.1101/​2020.09.09.287508]]** ​ |  Gu Y (2020) ​ | **[[https://​thebiogrid.org/​221568223561/​publication|Interaction network of SARS-CoV-2 with host receptome through spike protein]]** ​ | 
 |  **888800000106** ​ |  **[[https:/functional/​doi.org/​10.1101/​2020.08.29.273441|10.1101/​2020.08.29.273441]]** ​ |  Bojadzic D (2020) ​ | **[[https://​thebiogrid.org/​223562/​publication|Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19]]** ​ | 
 |  **888800000107** ​ |  **[[https://​doi.org/​10.1101/​2020.09.04.282558|10.1101/​2020.09.04.282558]]** ​ |  Bouwman KM (2020) ​ | **[[https://​thebiogrid.org/​223563/​publication|Multimerization- and glycosylation-geneticdependent receptor binding of SARS-analysisCoV-2 spike proteins]]** ​ | 
 |  **888800000108** ​ |  **[[https://​doi.org/​10.1101/​2020.08.28.271601|10.1101/​2020.08.28.271601]]** ​ |  Dash P (2020) ​ | **[[https://​thebiogrid.org/​223564/​publication|Sequence analysis ​of Indian SARS-viralCoV-2 isolates shows a stronger interaction of mutated ​receptor ​binding domain with ACE2 receptor]]** ​ | 
 |  **888800000109** ​ |  **[[https://​doi.org/​10.1101/​2020.08.28.269175|10.1101/​2020.08.28.269175]]** ​ |  St-ace2Germain JR (2020) ​ | **[[https://​thebiogrid.org/​223565/​publication|A SARS-orthologsCoV-reveals2 BioID-broad-potentialbased virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-range19 research]]** ​ | 
 |  **888800000111** ​ |  **[[https://​doi.org/​10.1101/​2020.09.04.280081|10.1101/​2020.09.04.280081]]** ​ |  Qiang X (2020) ​ | **[[https://​thebiogrid.org/​223567/​publication|Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.]]** ​ | 
 |  **888800000112** ​ |  **[[https://​doi.org/​10.1101/​2020.09.09.287987|10.1101/​2020.09.09.287987]]** ​ |  Durdagi S (2020) ​ | **[[https://​thebiogrid.org/​223568/​publication|Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations ​of SARS-sarsCoV-cov2 Main Protease Active Site for Improved Drug Repurposing]]** ​ | 
 |  **888800000113** ​ |  **[[https://​doi.org/​10.1101/​2020.09.01.277954|10.1101/​2020.09.01.277954]]** ​ |  Bartolome A (2020) ​ | **[[https://​thebiogrid.org/​223569/​publication|Angiotensin converting enzyme 2 is a novel target of the secretase complex]]** ​ | 
 |  **888800000115** ​ |  **[[https://​doi.org/​10.1101/​2020.09.09.289488|10.1101/​2020.09.09.289488]]** ​ |  Kotani N (2020) ​ | **[[https://​thebiogrid.org/​223571/​publication|Candidate screening of host cell membrane proteins involved in SARS-CoV-2 entry]]** ​ | 
 |  **888800000116** ​ |  **[[https://​doi.org/​10.1101/​2020.08.27.270637|10.1101/​2020.08.27.html270637]]** ​ |  Flower TG (2020) ​ | **[[https://​thebiogrid.org/​223572/​publication|Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion]]**  | 
 |  **888800000021888800000117**  |  **[[https://​doi.org/​10.1101/​2020.0409.21.053017307439|10.1101/​2020.0409.21.053017307439]]**  |  ​Walker A Wang X (2020) ​ | **[[https://​thebiogrid.org/​221569223769/​publication/enisamium|Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-isCoV-2 evolution]]** ​ | 
 |  **888800000118** ​ |  **[[https://​doi.org/​10.1101/​2020.09.14.295956|10.1101/​2020.09.14.295956]]** ​ |  Lin C (2020) ​ | **[[https://​thebiogrid.org/​223770/​publication|Ceftazidime Is a Potential Drug to Inhibit SARS-smallCoV-molecule2 Infection In Vitro by Blocking Spike Protein-inhibitorACE2 Interaction]]** ​ | 
 |  **888800000119** ​ |  **[[https://​doi.org/​10.1101/​2020.09.16.297366|10.1101/​2020.09.16.297366]]** ​ |  Sagar S (2020) ​ | **[[https://​thebiogrid.org/​223771/​publication|Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells]]** ​ | 
 |  **888800000120** ​ |  **[[https://​doi.org/​10.1101/​2020.09.18.301952|10.1101/​2020.09.18.301952]]** ​ |  Xiao T (2020) ​ | **[[https://​thebiogrid.org/​223772/​publication|A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro]]** ​ | 
 |  **888800000121** ​ |  **[[https://​doi.org/​10.1101/​2020.09.16.297945|10.1101/​2020.09.16.297945]]** ​ |  Meyer B (2020) ​ | **[[https://​thebiogrid.org/​223773/​publication|Characterisation ​of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing]]** ​ | 
 |  **888800000122** ​ |  **[[https://​doi.org/​10.1101/​2020.09.22.308338|10.1101/​2020.09.22.308338]]** ​ |  Wagner TR (2020) ​ | **[[https://​thebiogrid.org/​223774/​publication|NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response]]** ​ | 
 |  **888800000123** ​ |  **[[https://​doi.org/​10.1101/​2020.09.20.297242|10.1101/​2020.09.20.297242]]** ​ |  Ren W (2020) ​ | **[[https://​thebiogrid.org/​223775/​publication|Comparative analysis reveals ​the species-influenzaspecific genetic determinants of ACE2 required for SARS-CoV-2 entry]]** ​ | 
 |  **888800000124** ​ |  **[[https://​doi.org/​10.1101/​2020.09.13.295691|10.1101/​2020.09.13.295691]]** ​ |  Olaleye OA (2020) ​ | **[[https://​thebiogrid.org/​223776/​publication|Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein'​s Receptor Binding Domain and Recombinant Human ACE2.]]** ​ | 
 |  **888800000125** ​ |  **[[https://​doi.org/​10.1101/​2020.09.16.300319|10.1101/​2020.09.16.300319]]** ​ |  Tada T (2020) ​ | **[[https://​thebiogrid.org/​223777/​publication|A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-virusCoV-2 infection in cell culture]]** ​ | 
 |  **888800000126** ​ |  **[[https://​doi.org/​10.1101/​2020.09.16.299891|10.1101/​2020.09.16.299891]]** ​ |  Higuchi Y (2020) ​ | **[[https://​thebiogrid.org/​223778/​publication|High affinity modified ACE2 receptors prevent SARS-CoV-2 infection]]** ​ | 
 |  **888800000127** ​ |  **[[https://​doi.org/​10.1101/​2020.09.16.20190694|10.1101/​2020.09.16.20190694]]** ​ |  Ichimura T (2020) ​ | **[[https://​thebiogrid.org/​223779/​publication|KIM-1/​TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney]]** ​ | 
 |  **888800000128** ​ |  **[[https://​doi.org/​10.1101/​2020.11.04.361154|10.1101/​2020.11.04.361154]]** ​ |  de Vries (2020) ​ | **[[https://​thebiogrid.org/​225841/​publication|Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-sarsCoV-cov2 transmission in ferrets]]** ​ | 
 |  **888800000129** ​ |  **[[https://​doi.org/​10.1101/​2020.10.13.336800|10.1101/​2020.10.13.336800]]** ​ |  Yan R (2020) ​ | **[[https://​thebiogrid.org/​225985/​publication|Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies]]** ​ | 
 |  **888800000130** ​ |  **[[https://​doi.org/​10.1101/​2020.09.27.315796|10.1101/​2020.09.27.315796]]** ​ |  Bauer MS (2020) ​ | **[[https://​thebiogrid.org/​225986/​publication|A Tethered Ligand Assay to Probe the SARS-rnaCoV-polymerases2 ACE2 Interaction under Constant Force]]** ​ | 
 |  **888800000131** ​ |  **[[https://​doi.org/​10.1101/​2020.10.06.328112|10.1101/​2020.10.06.html328112]]** ​ |  Lutomski CA (2020) ​ | **[[https://​thebiogrid.org/​225987/​publication|Autoproteolytic Products of the SARS-CoV-2 Nucleocapsid Protein are Primed for Antibody Evasion and Virus Proliferation]]**  | 
 |  **888800000022888800000132**  |  **[[https://​doi.org/​10.1101/​2020.0410.1731.047498363473|10.1101/​2020.10.31.363473]]** ​ |  Stevens BR (2020) ​ | **[[https://​thebiogrid.org/​225988/​publication|TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes,​ and kidney]]** ​ | 
 |  **888800000133** ​ |  **[[https://​doi.org/​10.1101/​2020.10.23.350348|10.1101/​2020.10.23.350348]]** ​ |  Tang X (2020) ​ | **[[https://​thebiogrid.org/​225989/​publication|Transferrin receptor is another receptor for SARS-CoV-2 entry]]** ​ | 
 |  **888800000134** ​ |  **[[https://​doi.org/​10.1101/​2020.11.04.17361576|10.0474981101/​2020.11.04.361576]]**  |  ​Rosas Lemus M Li W (2020) ​ | **[[https://​thebiogrid.org/​221570225990/​publication|Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network]]** ​ | 
 |  **888800000135** ​ |  **[[https:/the/​doi.org/​10.1101/​2020.10.29.352450|10.1101/​2020.10.29.352450]]** ​ |  Bakovic A (2020) ​ | **[[https://​thebiogrid.org/​225991/​publication|Brilacidin,​ a COVID-crystal19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-structureCoV-2]]**  | 
 |  **888800000136** ​ |  **[[https://​doi.org/​10.1101/​2020.10.26.356048|10.1101/​2020.10.26.356048]]** ​ |  Liu G (2020) ​ | **[[https://​thebiogrid.org/​225992/​publication|ISG15-dependent Activation ​of the RNA Sensor MDA5 and its Antagonism by the SARS-nsp10CoV-nsp162 papain-heterodimerlike protease]]** ​ | 
 |  **888800000137** ​ |  **[[https://​doi.org/​10.1101/​2020.10.16.342097|10.1101/​2020.10.16.342097]]** ​ |  Gao X (2020) ​ | **[[https://​thebiogrid.org/​225993/​publication|Duple extinguishment of COVID-from19: single compound synergized inhibition of SARS-sarsCoV-cov2 replication and direct suppression of inflammatory cytokines in vitro/​vivo]]** ​ | 
 |  **888800000138** ​ |  **[[https://​doi.org/​10.1101/​2020.10.13.337584|10.1101/​2020.10.13.337584]]** ​ |  Roy A (2020) ​ | **[[https://​thebiogrid.org/​225994/​publication|ACIS,​ A Novel KepTide(tm),​ Binds to ACE-2in2 Receptor and Inhibits the Infection of SARS-complexCoV2 Virus in vitro in Primate Kidney Cells: Therapeutic Implications for COVID-19]]** ​ | 
 |  **888800000139** ​ |  **[[https://​doi.org/​10.1101/​2020.10.30.361873|10.1101/​2020.10.30.361873]]** ​ |  Andring JT (2020) ​ | **[[https://​thebiogrid.org/​225995/​publication|Amino acid transporter B0AT1 influence on ADAM17 interactions ​with SARS-sCoV-adenosylmethionine2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes]]** ​ | 
 |  **888800000140** ​ |  **[[https://​doi.htmlorg/​10.1101/​2020.10.23.347534|10.1101/​2020.10.23.347534]]** ​ |  Mellott D (2020) ​ | **[[https://​thebiogrid.org/​225996/​publication|A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells]]**  | 
 |  **888800000023888800000141**  |  **[[https://​doi.org/​10.1101/​2020.0410.1906.048710327742|10.1101/​2020.0410.1906.048710327742]]**  |  ​Zhao X Kliche J (2020) ​ | **[[https://​thebiogrid.org/​221571225997/​publication|Cytoplasmic short linear motifs in ACE2 and integrin beta3 link SARS-CoV-2 host cell receptors to endocytosis and autophagy]]** ​ | 
 |  **888800000142** ​ |  **[[https://​doi.org/​10.1101/​2020.10.18.344622|10.1101/​2020.10.18.344622]]** ​ |  Chan KK (2020) ​ | **[[https://​thebiogrid.org/​225998/​publication|An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants]]** ​ | 
 |  **888800000143** ​ |  **[[https://​doi.org/​10.1101/​2020.11.01.363788|10.1101/​2020.11.01.363788]]** ​ |  Sun J (2020) ​ | **[[https://​thebiogrid.org/​225999/​publication|Discovery of five HIV nucleoside analog reverse-transcriptase inhibitors (NRTIs) as potent inhibitors against the RNA-dependent RNA polymerase (RdRp) of SARS-CoV and 2019-nCoV]]** ​ | 
 |  **888800000144** ​ |  **[[https://​doi.org/​10.1101/​2020.10.30.362335|10.1101/​2020.10.30.362335]]** ​ |  Hu Y (2020) ​ | **[[https://​thebiogrid.org/​226000/​publication|Boceprevir,​ calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture]]** ​ | 
 |  **888800000145** ​ |  **[[https://​doi.org/​10.1101/​2020.10.11.335299|10.1101/​2020.10.11.335299]]** ​ |  Gobeil S (2020) ​ | **[[https://​thebiogrid.org/​226001/​publication|D614G mutation alters SARS-CoV-2 spike conformational dynamics ​and protease cleavage susceptibility at the S1/S2 junction]]** ​ | 
 |  **888800000146** ​ |  **[[https://​doi.org/​10.1101/​2020.10.06.327445|10.1101/​2020.10.06.327445]]** ​ |  Flynn RA (2020) ​ | **[[https://​thebiogrid.org/​226002/​publication|Systematic discovery and functional interrogation of SARS-differentialCoV-animal2 viral RNA-ace2host protein interactions during infection]]** ​ | 
 |  **888800000147** ​ |  **[[https://​doi.org/​10.1101/​2020.09.24.312553|10.1101/​2020.09.24.312553]]** ​ |  Li Y (2020) ​ | **[[https://​thebiogrid.org/​226003/​publication|SARS-receptorCoV-usage2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes]]** ​ | 
 |  **888800000148** ​ |  **[[https://​doi.org/​10.1101/​2020.10.22.351569|10.1101/​2020.10.22.351569]]** ​ |  Nguyen HT (2020) ​ | **[[https://​thebiogrid.org/​226004/​publication|Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects]]** ​ | 
 |  **888800000149** ​ |  **[[https://​doi.org/​10.1101/​2020.10.22.351056|10.1101/​2020.10.22.351056]]** ​ |  Bojadzic D (2020) ​ | **[[https://​thebiogrid.org/​226005/​publication|Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2]]** ​ | 
 |  **888800000150** ​ |  **[[https://​doi.org/​10.1101/​2020.10.08.20209114|10.1101/​2020.10.08.20209114]]** ​ |  Wu F (2020) ​ | **[[https://​thebiogrid.org/​226006/​publication|Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis]]** ​ | 
 |  **888800000151** ​ |  **[[https://​doi.org/​10.1101/​2020.09.30.317818|10.1101/​2020.09.30.317818]]** ​ |  Hsu AC-Y (2020) ​ | **[[https://​thebiogrid.org/​226007/​publication|SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated ​by Spike-sarsantagonistic peptide and FDA-covapproved ER stress and MAP kinase inhibitors in vitro]]** ​ | 
 |  **888800000152** ​ |  **[[https://​doi.org/​10.1101/​2020.11.05.369264|10.1101/​2020.11.05.369264]]** ​ |  Soh WT (2020) ​ | **[[https://​thebiogrid.org/​226008/​publication|The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN]]** ​ | 
 |  **888800000153** ​ |  **[[https://​doi.org/​10.1101/​2020.12.02.408153|10.1101/​2020.12.02.html408153]]** ​ |  Roth A (2020) ​ | **[[https://​thebiogrid.org/​226406/​publication|LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro]]**  | 
 |  **888800000024888800000154**  |  **[[https://​doi.org/​10.1101/​2020.0411.2624.06170520237628|10.1101/​2020.0411.2624.06170520237628]]**  |  ​Viswanathan T Al Ahmad M (2020) ​ | **[[https://​thebiogrid.org/​221642226407/​publication|Development of an Optical Assay to Detect SARS-CoV-2 Spike Protein Binding Interactions with ACE2 and Disruption of these Interactions Using Electric Current]]** ​ | 
 |  **888800000155** ​ |  **[[https:/structural/​doi.org/​10.1101/​2020.12.06.413443|10.1101/​2020.12.06.413443]]** ​ |  Svilenov HL (2020) ​ | **[[https://​thebiogrid.org/​226408/​publication|Efficient inhibition of SARS-basisCoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region]]** ​ | 
 |  **888800000156** ​ |  **[[https://​doi.org/​10.1101/​2020.12.01.406116|10.1101/​2020.12.01.406116]]** ​ |  Tito A (2020) ​ | **[[https://​thebiogrid.org/​226409/​publication|A pomegranate peel extract as inhibitor ​of SARS-rnaCoV-cap2 Spike binding to human ACE2 (in vitro): a promising source of novel antiviral drugs]]** ​ | 
 |  **888800000157** ​ |  **[[https://​doi.org/​10.1101/​2020.11.24.393629|10.1101/​2020.11.24.393629]]** ​ |  Wang X (2020) ​ | **[[https://​thebiogrid.org/​226410/​publication|Double Lock of a Potent Human Monoclonal Antibody against SARS-modificationCoV-2]]**  | 
 |  **888800000158** ​ |  **[[https://​doi.org/​10.1101/​2020.12.03.409441|10.1101/​2020.12.03.409441]]** ​ |  Rossetti GG (2020) ​ | **[[https://​thebiogrid.org/​226411/​publication|Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified ​by in silico screens]]** ​ | 
 |  **888800000159** ​ |  **[[https://​doi.org/​10.1101/​2020.11.11.378018|10.1101/​2020.11.11.378018]]** ​ |  Eberle RJ (2020) ​ | **[[https://​thebiogrid.org/​226412/​publication|The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-sarsCoV-cov2 3CLpro]]** ​ | 
 |  **888800000160** ​ |  **[[https://​doi.org/​10.1101/​2020.11.12.378422|10.1101/​2020.11.12.378422]]** ​ |  Guenther S (2020) ​ | **[[https://​thebiogrid.org/​226413/​publication|Inhibition of SARS-CoV-2 main protease by allosteric drug-coronavirusbinding]]** ​ | 
 |  **888800000161** ​ |  **[[https://​doi.htmlorg/​10.1101/​2020.12.06.412759|10.1101/​2020.12.06.412759]]** ​ |  Calistri A (2020) ​ | **[[https://​thebiogrid.org/​226414/​publication|The new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2]]**  | 
 |  **888800000025888800000162**  |  **[[https://​doi.org/​10.1101/​2020.0412.2903.068890409318|10.1101/​2020.0412.2903.068890409318]]**  |  ​Rut W Bertoglio F (2020) ​ | **[[https://​thebiogrid.org/​221777226415/​publication|A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations]]** ​ | 
 |  **888800000163** ​ |  **[[https:/activity/​doi.org/​10.1101/​2020.11.06.368191|10.1101/​2020.11.06.368191]]** ​ |  Kraus A (2020) ​ | **[[https://​thebiogrid.org/​226416/​publication|A zebrafish model for COVID-profiling19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2]]** ​ | 
 |  **888800000164** ​ |  **[[https://​doi.org/​10.1101/​2020.12.23.424149|10.1101/​2020.12.23.424149]]** ​ |  Noske G (2020) ​ | **[[https://​thebiogrid.org/​226619/​publication|A Crystallographic Snapshot ​of SARS-sarsCoV-cov2 Main Protease Maturation Process]]** ​ | 
 |  **888800000165** ​ |  **[[https://​doi.org/​10.1101/​2020.12.18.423427|10.1101/​2020.12.18.423427]]** ​ |  Zhao Y (2020) ​ | **[[https://​thebiogrid.org/​226620/​publication|SARS-CoV-2 spike protein interacts with and activates TLR4]]** ​ | 
 |  **888800000166** ​ |  **[[https://​doi.org/​10.1101/​2020.12.19.423537|10.1101/​2020.12.19.423537]]** ​ |  Kitamura N (2020) ​ | **[[https://​thebiogrid.org/​226621/​publication|An expedited approach towards the rationale design of non-plprocovalent SARS-CoV-2 main protease ​inhibitors with in vitro antiviral activity]]** ​ | 
 |  **888800000167** ​ |  **[[https://​doi.org/​10.1101/​2020.12.23.424171|10.1101/​2020.12.23.424171]]** ​ |  Schmitz A (2020) ​ | **[[https://​thebiogrid.org/​226622/​publication|A SARS-providesCoV-structural2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism]]** ​ | 
 |  **888800000168** ​ |  **[[https://​doi.org/​10.1101/​2020.12.31.424961|10.1101/​2020.12.31.424961]]** ​ |  Chen Z (2021) ​ | **[[https://​thebiogrid.org/​226623/​publication|Comprehensive analysis of the host-frameworkvirus interactome of SARS-forCoV-anti2]]**  | 
 |  **888800000169** ​ |  **[[https://​doi.org/​10.1101/​2020.12.21.423721|10.1101/​2020.12.21.423721]]** ​ |  Avolio E (2020) ​ | **[[https://​thebiogrid.org/​226624/​publication|The SARS-covidCoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease]]** ​ | 
 |  **888800000170** ​ |  **[[https://​doi.org/​10.1101/​2020.12.19.423584|10.1101/​2020.12.19.423584]]** ​ |  Garcia-drugDorival I (2020) ​ | **[[https://​thebiogrid.org/​226625/​publication|Identification of NPC1 as a novel SARS-designCoV-2 intracellular target]]** ​ | 
 |  **888800000171** ​ |  **[[https://​doi.org/​10.1101/​2020.12.26.424423|10.1101/​2020.12.26.html424423]]** ​ |  Durdagi S (2020) ​ | **[[https://​thebiogrid.org/​226626/​publication|The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies]]**  | 
 |  **888800000026888800000172**  |  **[[https://​doi.org/​10.1101/​2020.0412.2718.063180423415|10.1101/​2020.0412.2718.063180423415]]**  |  ​Hillen HS Madan T (2020) ​ | **[[https://​thebiogrid.org/​221778226627/​publication|A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples]]** ​ | 
 |  **888800000173** ​ |  **[[https:/structure/​doi.org/​10.1101/​2020.12.29.424698|10.1101/​2020.12.29.424698]]** ​ |  Yang X (2020) ​ | **[[https://​thebiogrid.org/​226628/​publication|An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro]]** ​ | 
 |  **888800000174** ​ |  **[[https://​doi.org/​10.1101/​2020.12.20.422820|10.1101/​2020.12.20.422820]]** ​ |  Fiedler S (2020) ​ | **[[https://​thebiogrid.org/​226629/​publication|In vitro measurements ​of protein-replicatingprotein interactions show that antibody affinity governs the inhibition of SARS-sarsCoV-cov2 spike/ACE2 binding in convalescent serum]]** ​ | 
 |  **888800000175** ​ |  **[[https://​doi.org/​10.1101/​2020.12.22.422708|10.1101/​2020.12.22.422708]]** ​ |  Shepley-McTaggart A (2020) ​ | **[[https://​thebiogrid.org/​226630/​publication|SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-polymeraseDomain-2 of Host Tight Junction Protein ZO1]]** ​ | 
 |  **888800000176** ​ |  **[[https://​doi.htmlorg/​10.1101/​2020.12.18.423418|10.1101/​2020.12.18.423418]]** ​ |  Hsieh M-H (2020) ​ | **[[https://​thebiogrid.org/​226631/​publication|Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro]]**  | 
 |  **888800000027888800000177**  |  **[[https://​doi.org/​10.1101/​2020.0412.16.422677|10.1101/​2020.12.16.422677]]** ​ |  Kuzikov M (2020) ​ | **[[https://​thebiogrid.org/​226632/​publication|Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen]]** ​ | 
 |  **888800000178** ​ |  **[[https://​doi.org/​10.1101/​2020.12.30.424801|10.1101/​2020.12.30.424801]]** ​ |  Woo HG (2020) ​ | **[[https://​thebiogrid.org/​226633/​publication|Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro]]** ​ | 
 |  **888800000179** ​ |  **[[https://​doi.org/​10.1101/​2020.12.26.424422|10.1101/​2020.12.26.424422]]** ​ |  Xu W (2020) ​ | **[[https://​thebiogrid.org/​226634/​publication|Extensive High-Order Complexes within SARS-CoV-2 Proteome Revealed by Compartmentalization-Aided Interaction Screening]]** ​ | 
 |  **888800000180** ​ |  **[[https://​doi.org/​10.1101/​2020.12.09.417741|10.1101/​2020.12.09.417741]]** ​ |  Armstrong L (2020) ​ | **[[https://​thebiogrid.org/​226635/​publication|Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies]]** ​ | 
 |  **888800000181** ​ |  **[[https://​doi.org/​10.1101/​2020.12.29.068098424682|10.1101/​2020.0412.29.068098424682]]**  |  ​Sun Z Kuznetsov A (2020) ​ | **[[https://​thebiogrid.org/​221779226636/​publication|ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1]]** ​ | 
 |  **888800000182** ​ |  **[[https:/mass/​doi.org/​10.1101/​2021.01.21.427657|10.1101/​2021.01.21.427657]]** ​ |  Choi R (2021) ​ | **[[https://​thebiogrid.org/​226858/​publication|High-spectrometrythroughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-analysisCoV2 nsp15 endoribonuclease to identify small-molecule inhibitors ​of viral activity.]]** ​ | 
 |  **888800000183** ​ |  **[[https://​doi.org/​10.1101/​2021.01.12.426388|10.1101/​2021.01.12.426388]]** ​ |  Kneller DW (2021) ​ | **[[https://​thebiogrid.org/​226859/​publication|Inhibitor Binding Modulates Protonation States in the Active Site of SARS-newlyCoV-emerging2 Main Protease]]** ​ | 
 |  **888800000184** ​ |  **[[https://​doi.org/​10.1101/​2021.01.17.427000|10.1101/​2021.01.17.427000]]** ​ |  Wan Y (2021) ​ | **[[https://​thebiogrid.org/​226860/​publication|Comprehensive mapping of SARS-coronavirusCoV-hcov2 interactions in vivo reveals functional virus-host interactions]]** ​ | 
 |  **888800000185** ​ |  **[[https://​doi.org/​10.1101/​2021.01.19.427194|10.1101/​2021.01.19.427194]]** ​ |  Tian R (2021) ​ | **[[https://​thebiogrid.org/​226861/​publication|BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2]]** ​ | 
 |  **888800000186** ​ |  **[[https://​doi.org/​10.1101/​2021.01.11.426269|10.1101/​2021.01.11.426269]]** ​ |  Zhu X (2021) ​ | **[[https://​thebiogrid.org/​226862/​publication|Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody]]** ​ | 
 |  **888800000187** ​ |  **[[https://​doi.org/​10.1101/​2021.01.05.425478|10.1101/​2021.01.05.425478]]** ​ |  Kamle S (2021) ​ | **[[https://​thebiogrid.org/​226863/​publication|Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19]]** ​ | 
 |  **888800000188** ​ |  **[[https://​doi.org/​10.1101/​2021.01.14.426695|10.1101/​2021.01.14.426695]]** ​ |  Carnell GW (2021) ​ | **[[https://​thebiogrid.org/​226864/​publication|SARS-CoV-2 ​spike protein arrested in the closed state induces potent neutralizing responses]]** ​ | 
 |  **888800000189** ​ |  **[[https://​doi.org/​10.1101/​2021.01.13.21249429|10.1101/​2021.01.13.21249429]]** ​ |  Hultstrom M (2021) ​ | **[[https://​thebiogrid.org/​226865/​publication|Elevated Angiopoietin-s2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients]]** ​ | 
 |  **888800000190** ​ |  **[[https://​doi.org/​10.1101/​2021.01.19.427324|10.1101/​2021.01.19.427324]]** ​ |  Suryadevara N (2021) ​ | **[[https://​thebiogrid.org/​226866/​publication|Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein]]**  | 
 |  **888800000191** ​ |  **[[https://​doi.org/​10.1101/​2021.01.11.426218|10.1101/​2021.01.11.426218]]** ​ |  Rapp M (2021) ​ | **[[https://​thebiogrid.org/​226867/​publication|Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class]]** ​ | 
 |  **888800000192** ​ |  **[[https://​doi.org/​10.1101/​2021.01.07.425745|10.1101/​2021.01.07.425745]]** ​ |  Saramago M (2021) ​ | **[[https://​thebiogrid.org/​226868/​publication|New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'​-5'​ exoribonucleolytic activity on SARS-CoV-2]]** ​ | 
 |  **888800000193** ​ |  **[[https://​doi.org/​10.1101/​2021.01.12.426042|10.1101/​2021.01.12.426042]]** ​ |  Siniavin AE (2021) ​ | **[[https://​thebiogrid.org/​226869/​publication|Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor]]** ​ | 
 |  **888800000194** ​ |  **[[https://​doi.org/​10.1101/​2021.01.07.425806|10.1101/​2021.01.07.425806]]** ​ |  Bell BN (2021) ​ | **[[https://​thebiogrid.org/​226870/​publication|Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library]]** ​ | 
 |  **888800000195** ​ |  **[[https://​doi.org/​10.1101/​2021.01.20.427368|10.1101/​2021.01.20.427368]]** ​ |  Carlos AJ (2021) ​ | **[[https://​thebiogrid.org/​226871/​publication|GRP78 binds SARS-ace2CoV-reveals2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro]]** ​ | 
 |  **888800000196** ​ |  **[[https://​doi.org/​10.1101/​2021.01.05.425516|10.1101/​2021.01.05.425516]]** ​ |  Verma R (2021) ​ | **[[https://​thebiogrid.org/​226872/​publication|RNA-camouflagingprotein interaction analysis of SARS-glycansCoV-2 5'- and 3'-uniqueuntranslated regions identifies an antiviral role of lysosome-postassociated membrane protein-translational2]]**  | 
 |  **888800000197** ​ |  **[[https://​doi.org/​10.1101/​2021.01.29.428890|10.1101/​2021.01.29.428890]]** ​ |  Berndt AJ (2021) ​ | **[[https://​thebiogrid.org/​227046/​publication|Recombinant production of a functional SARS-modificationsCoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii]]** ​ | 
 |  **888800000198** ​ |  **[[https://​doi.htmlorg/​10.1101/​2021.01.29.428834|10.1101/​2021.01.29.428834]]** ​ |  Bayarri-Olmos R (2021) ​ | **[[https://​thebiogrid.org/​227047/​publication|The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization]]**  | 
 |  **888800000028888800000199**  |  **[[https://​doi.org/​10.1101/​20202021.0502.03.073080429601|10.1101/20202021.0502.03.073080429601]]**  |  ​Vuong W Prahlad J (20202021)  | **[[https://​thebiogrid.org/​221830227048/​publication|Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain]]** ​ | 
 |  **888800000200** ​ |  **[[https:/feline/​doi.org/​10.1101/​2021.02.03.429625|10.1101/​2021.02.03.429625]]** ​ |  Khalili Yazdi A (2021) ​ | **[[https://​thebiogrid.org/​227049/​publication|A high-coronavirusthroughput radioactivity-drugbased assay for screening SARS-inhibitsCoV-2 nsp10-nsp16 complex]]** ​ | 
 |  **888800000201** ​ |  **[[https://​doi.org/​10.1101/​2021.02.01.429176|10.1101/​2021.02.01.429176]]** ​ |  Caillet-Saguy C (2021) ​ | **[[https://​thebiogrid.org/​227050/​publication|Host PDZ-containing proteins targeted by SARS-Cov-2]]** ​ | 
 |  **888800000202** ​ |  **[[https://​doi.org/​10.1101/​2021.02.11.430866|10.1101/​2021.02.11.430866]]** ​ |  Liu H (2021) ​ | **[[https://​thebiogrid.org/​227051/​publication|A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection]]** ​ | 
 |  **888800000203** ​ |  **[[https://​doi.org/​10.1101/​2021.02.02.429311|10.1101/​2021.02.02.429311]]** ​ |  Ma H (2021) ​ | **[[https://​thebiogrid.org/​227052/​publication|Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting ​the Spike Receptor-mainBinding Domain]]** ​ | 
 |  **888800000204** ​ |  **[[https://​doi.org/​10.1101/​2021.02.19.424337|10.1101/​2021.02.19.424337]]** ​ |  Devkota K (2021) ​ | **[[https://​thebiogrid.org/​227053/​publication|Probing the SAM Binding Site of SARS-proteaseCoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors]]** ​ | 
 |  **888800000205** ​ |  **[[https://​doi.org/​10.1101/​2021.02.13.431008|10.1101/​2021.02.13.431008]]** ​ |  Shen Z (2021) ​ | **[[https://​thebiogrid.org/​227054/​publication|Potent,​ Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures]]** ​ | 
 |  **888800000206** ​ |  **[[https://​doi.org/​10.1101/​2021.02.17.431617|10.1101/​2021.02.17.431617]]** ​ |  Bollavaram K (2021) ​ | **[[https://​thebiogrid.org/​227055/​publication|Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V]]**  | 
 |  **888800000207** ​ |  **[[https://​doi.org/​10.1101/​2021.01.31.429023|10.1101/​2021.01.31.429023]]** ​ |  Minasov G (2021) ​ | **[[https://​thebiogrid.org/​227056/​publication|Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'​-O-methyl transfer by SARS-CoV-2 nsp16]]** ​ | 
 |  **888800000208** ​ |  **[[https://​doi.org/​10.1101/​2021.02.03.429355|10.1101/​2021.02.03.429355]]** ​ |  Graham C (2021) ​ | **[[https://​thebiogrid.org/​227057/​publication|Impact ​of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-sarsCoV-cov2 Spike]]** ​ | 
 |  **888800000209** ​ |  **[[https://​doi.org/​10.1101/​2021.02.09.430451|10.1101/​2021.02.09.430451]]** ​ |  Spelios MG (2021) ​ | **[[https://​thebiogrid.org/​227058/​publication|A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding]]** ​ | 
 |  **888800000210** ​ |  **[[https://​doi.org/​10.1101/​2021.02.02.428884|10.1101/​2021.02.02.428884]]** ​ |  Zhang G (2021) ​ | **[[https://​thebiogrid.org/​227059/​publication|The basis of a more contagious 501Y.V1 variant of SARS-COV-2]]** ​ | 
 |  **888800000211** ​ |  **[[https://​doi.org/​10.1101/​2021.02.16.431021|10.1101/​2021.02.16.431021]]** ​ |  Arutyunova E (2021) ​ | **[[https://​thebiogrid.org/​227060/​publication|N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro]]** ​ | 
 |  **888800000212** ​ |  **[[https://​doi.org/​10.1101/​2021.02.07.429299|10.1101/​2021.02.07.429299]]** ​ |  Gu C (2021) ​ | **[[https://​thebiogrid.org/​227061/​publication|A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic ​and therapeutic efficacy against SARS-blocksCoV-virus2 in rhesus macaques]]** ​ | 
 |  **888800000213** ​ |  **[[https://​doi.org/​10.1101/​2021.02.04.429751|10.1101/​2021.02.04.429751]]** ​ |  Slavin M (2021) ​ | **[[https://​thebiogrid.org/​227062/​publication|Targeted in situ cross-replicationlinking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2]]** ​ | 
 |  **888800000214** ​ |  **[[https://​doi.htmlorg/​10.1101/​2021.02.08.430344|10.1101/​2021.02.08.430344]]** ​ |  Zhao H (2021) ​ | **[[https://​thebiogrid.org/​227063/​publication|Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids]]** ​ | 
 |  **888800000215** ​ |  **[[https://​doi.org/​10.1101/​2021.02.14.431117|10.1101/​2021.02.14.431117]]** ​ |  Tian F (2021) ​ | **[[https://​thebiogrid.org/​227064/​publication|Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2]]** ​ | 
 |  **888800000216** ​ |  **[[https://​doi.org/​10.1101/​2021.02.17.431755|10.1101/​2021.02.17.431755]]** ​ |  Zhao Y (2021) ​ | **[[https://​thebiogrid.org/​227065/​publication|SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses]]**  |
 
covid/unpublished.1591119138.txt.gz · Last modified: 2020/06/02 13:32 by biogridadmin